

Special Issue

Climate Change and Marine Natural Products

Message from the Guest Editors

Parasitic diseases, such as malaria, filariases, and Chagas disease continue to cause major health challenges for both human and agriculture health with particular challenges in tropical regions. However, the treatments of these diseases remains limited and the currently available anti-parasitic drugs provide significant challenges in regard to drug resistance and adverse effects. Marine natural products harbor great potential as controls of parasitic diseases and according to recent reports there are dozens of newly reported marine natural products showing anti-malarial, anti-leishmanial, and anti-trypanosomal activities. Advances in sample collection strategies, structure characterization, fermentation, metabolomics, assays screening and other related technologies continue to provide improvements in access to marine resources and advance the promise of marine-derived therapeutics for the control of parasitic diseases. In this Special Issue of Marine Drugs we are encouraging investigators to provide preliminary communications, research papers and reviews about compounds from marine origin with antiparasitic activity.

Guest Editors

Prof. Dr. Mark T. Hamann


Department of Drug Discovery, Medical University of South Carolina, Charleston, SC 29425, USA

Dr. Xiaoyan Chen

Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, SC, USA

Deadline for manuscript submissions

closed (31 May 2020)



Marine Drugs

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 9.6
Indexed in PubMed



mdpi.com/si/10940

Marine Drugs

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
marinedrugs@mdpi.com

[mdpi.com/journal/
marinedrugs](https://mdpi.com/journal/marinedrugs)





Marine Drugs

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 9.6
Indexed in PubMed



[mdpi.com/journal/
marinedrugs](https://mdpi.com/journal/marinedrugs)



About the Journal

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))